+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Atopic Dermatitis Market Size, Share and Trends Analysis by Region, Drug Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics, Others), Route of Administration (Injectable, Oral, Topical) and Segment Forecast, 2022-2027

  • PDF Icon

    Report

  • 107 Pages
  • November 2022
  • Region: Global
  • GlobalData
  • ID: 5699696
The Global Atopic Dermatitis market size was valued at US$6.8 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 10.3% during 2022-2027. The Global Atopic Dermatitis market report provides an executive-level overview of the atopic dermatits market worldwide today, with detailed forecasts of key indicators up to 2027.

This market intelligence report offers a thorough, forward-looking analysis of the global atopic dermatitismarket, and key product and platform stack in a concise format to help executives build proactive and profitable growth strategies.

The Atopic Dermatitis market size was valued at US$6.8 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 10.3% during the forecast period (2022-2027). The market is driven by the rising prevalence of atopic dermatitis, and the rising demand for bioligcs in treating AD.

Scope

  • Overview of atopic dermatitis market including industry trends, funding & deals, pipeline analysis, regulatory details, and product & company profile
  • Atopic Dermatitis market outlook: analysis as well as historical figures and forecasts of revenue opportunities from the product, technology, application and geographic segments.
  • Atopic Dermatitis market outlook: analysis as well as forecasts of revenue opportunities from the drug class segments.
  • Atopic Dermatitis market outlook: analysis as well as forecasts of revenue opportunities from the route of administrtaion segment.
  • The competitive landscape: an examination of the positioning of leading players in Atopic Dermatitis market.

Reasons to Buy

  • This market intelligence report offers a thorough, forward-looking analysis of the global Atopic Dermatitis market and key opportunities in a concise format to help executives build proactive and profitable growth strategies.
  • Accompanying the publisher's Forecast products, the report examines the assumptions and drivers behind ongoing and upcoming trends in Atopic Dermatitis markets.
  • The report also highlights key component, end-user, and technology segments.
  • With different charts and tables, the report is designed for an executive-level audience, boasting presentation quality.
  • The report provides an easily digestible market assessment for decision-makers built around in-depth information gathered from market players, which enables executives to quickly get up to speed with the current and emerging trends in Atopic Dermatitis market.

Table of Contents

CHAPTER 01 Executive Summary
1.1 Atopic Dermatitis Market Snapshot
1.2 Atopic Dermatitis Market- Key Findings
CHAPTER 02 Research Scope and Segmentation
CHAPTER 03 Technology Briefing
3.1 Disease Overview
3.1.1 ETIOLOGY AND PATHOPHYSIOLOGY
3.1.2 CLASSIFICATION OR STAGING SYSTEMS
3.2 Epidemiology
3.2.1 DISEASE BACKGROUND
3.2.2 RISK FACTORS AND COMORBIDITIES
3.2.3 GLOBAL AND HISTORICAL TRENDS
3.2.4 GLOBAL DATA EPIDEMIOLOGICAL FORECAST METHODOLOGY
3.2.5 EPIDEMIOLOGICAL FORECAST FOR DISEASE AD
3.2.6 DISCUSSION
CHAPTER 04 Disease Management
4.1 Diagnosis and Treatment Overview
4.2 KOL Insights on Disease Management
4.2.1 LONG TERM DISEASE CONTROL (EFFICACY)
4.2.2 TREATMENT APPROACH
CHAPTER 05 Competitive Assessment
5.1 Overview
CHAPTER 06 Unmet Needs and Opportunity Assessment
6.1 Overview
6.2 Lack of Therapeutic Options for Chronic Hand Eczema
6.3 Better Long-Term Disease Control and Management
6.4 More Tolerable Topical Treatment Options
6.5 Improved Patient Treatment Compliance
6.6 Increased Diversity in AD Clinical Trial Recruitment
CHAPTER 07 R&D Strategies
7.1 Overview
7.1.1 RISE OF THE JAK INHIBITORS
7.1.2 RISE OF INTERLEUKIN-INHIBITING BIOLOGICS
7.1.3 TARGETING NEW SIGNALING PATHWAYS/NOVEL TARGETS
7.2 Clinical Trials Design
7.2.1 CLINICAL TRIAL DESIGN IN AD
7.2.2 CLINICAL TRIAL DESIGN IN CHE
CHAPTER 08 Pipeline Assessment
8.1 Overview
8.2 Promising Drugs in Clinical Development
8.2.1 MILD TO MODERATE AGENTS
8.2.2 MODERATE-TO-SEVERE AGENTS
CHAPTER 09 Pipeline Valuation Analysis
9.1 Overview
9.2 Competitive Assessment
9.2.1 SYSTEMIC AGENTS
9.2.2 TOPICAL AGENTS
CHAPTER 010 Current and Future Players
10.1 Overview
10.2 Deal-Making Trends
CHAPTER 011 Atopic Dermatitis Industry Trends Analysis
11.1 Atopic Dermatitis Market Structure - PORTER’s Analysis
  • Global Atopic Dermatitis PORTER’s Five Force Analysis
CHAPTER 012 Global Atopic Dermatitis Revenue Opportunity
12.1 Global Atopic Dermatitis Market
12.2 COVID-19 Impact
CHAPTER 013 Atopic Dermatitis Drug Class Outlook
13.1 Atopic Dermatitis - Drug Class Deep Dive
13.1.1 CORTICOSTEROIDS
13.1.2 CALCINEURIN INHIBITORS
13.1.3 PDE4 INHIBITORS
13.1.4 BIOLOGICS
13.1.5 OTHER DRUG CLASSES
CHAPTER 014 Atopic Dermatitis Route of Administration Outlook
14.1 Atopic Dermatitis - Route of Administration Deep Dive
14.1.1 INJECTABLE
14.1.2 ORAL
14.1.3 TOPICAL
CHAPTER 015 Atopic Dermatitis Regional Outlook
15.1 Atopic Dermatitis - Regional Deep Dive
15.1.1 NORTH AMERICA
15.1.2 EUROPE
15.1.3 ASIA-PACIFIC
15.1.4 ROW
CHAPTER 016 Trends, Drivers, and Challenges
16.1 Atopic Dermatitis - Market Trends
16.1.1 CONSTANT COMPETITION TO LAUNCH NEW DRUGS
16.2 Atopic Dermatitis - Market Drivers
16.2.1 RISING PREVALENCE OF ATOPIC DERMATITIS
16.2.2 THE RISING DEMAND FOR BIOLOGICS IN ATOPIC DERMATITIS
16.3 Atopic Dermatitis - Market Challenges
16.3.1 INCREASE OF HYPERSENSITIVE REACTION LEADING TO PRODUCT RECALLS
16.3.2 HIGH TREATMENT COST, AND LACK OF REIMBURSEMENT GUIDELINES IN DEVELOPING COUNTRIES.
CHAPTER 017 Global Atopic Dermatitis Competitive Landscape
CHAPTER 018 Appendix
18.1 Abbreviations
18.2 Methodology
18.3 Key Themes Impacting the Pharmaceutical Industry
18.4 About the Publisher
  • Contact the Publisher
  • Contact the Publisher
List of Tables
Table 1 Key Trends Overview
Table 2 Research Scope And Segmentation
Table 3 Risk Factors and Comorbidities for AD
Table 4 Treatment Guidelines for AD.
Table 5 Atopic Dermatitis Market
Table 6 Atopic Dermatitis by Products, 2020-2027 ($Mn)
Table 7 Atopic Dermatitis by Route of Administration, 2020-2027 ($Mn)
Table 8 Atopic Dermatitis by Region, 2020-2027 ($Mn)
Table 9 North America Atopic Dermatitis by Country, 2020-2027 ($Mn)
Table 10 Asia-Pacific Atopic Dermatitis by Country, 2020-2027 ($Mn)
List of Figures
Figure 1 Market Snapshot ($Mn)
Figure 2 Key Segment Performance Snapshot
Figure 4 Major Drug Targets for AD Treatment
Figure 5 Major Drug Targets for AD Treatment
Figure 3 7MM, Age-Specific 12-Month Diagnosed Prevalent Cases of AD, N, Men and Women, 2020
Figure 4 7MM, Sex-Specific 12-Month Diagnosed Prevalent Cases of AD, N, All Ages, 2020
Figure 5 7MM, 12-Month Diagnosed Prevalent Cases by Severity, Men and Women, N, All Ages, 2020
Figure 6 Flowchart of the Diagnosis and Management of AD
Figure 7 Overview of the Development Pipeline in AD
Figure 8 Competitive Assessment of Marketed and Pipeline Systemic Drugs Benchmarked Against the SOC, Dupixent
Figure 9 Competitive Assessment of Marketed and Pipeline Systemic Drugs Benchmarked Against the SOC, Dupixent
Figure 10 Global Atopic Dermatitis PORTER’s Five Force Analysis
Figure 11 Global Atopic Dermatitis Market - Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 12 Atopic Dermatitis by Drug Class- Market Overview ($Mn)
Figure 13 Atopic Dermatitis by Drug Class Share - 2021 & 2027 (%)
Figure 14 Corticosteroids Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 15 Calcineurin Inhibitors Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 16 PDE4 Inhibitors Market Revenue Opportunity Forecast, 2020-2027 ($Mn
Figure 17 Biologics Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 18 Other Drug Classes Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 19 Atopic Dermatitis by Route of Administration- Market Overview ($Mn
Figure 20 Atopic Dermatitis by Route of Administration Share - 2021 & 2027 (%)
Figure 21 Injectable Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 22 Oral Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 23 Topical Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 24 Global Atopic Dermatitis by Region- Market Overview ($Mn)
Figure 25 Global Atopic Dermatitis by Region Share - 2021 & 2027 (%)
Figure 26 North America Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 27 Europe Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 28 Asia-Pacific Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 29 ROW Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Sanofi
  • Pfizer Inc.
  • LEO Pharma Inc
  • Regeneron Pharmaceuticals Inc.
  • AbbVie Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • GALDERMA LABORATORIES, L.P.
  • Incyte Corporation
  • Novartis AG